Open Your FREE Demat Account Now!

Zim Laboratories Ltd. Share Price

NSE
BSE

NSE : ZIMLAB

BSE : 541400

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹147.00

High

₹153.10

Price Summary

Previous Close ₹147.80
Day's Range ₹147.00 - ₹153.10
Open ₹148.00
52 Week Range ₹59.31 - ₹159.81
Volume 1,36,901
Market Cap ₹0.00
Previous Close ₹147.95
Day's Range ₹146.55 - ₹151.60
Open ₹147.90
52 Week Range ₹59.72 - ₹160.10
Volume 6,013
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 205.09
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 383.15
TTM EPS (₹) 0.39
P/E Ratio 54.87
Book Value(₹) 2.72
PAT Margin (%) 1.56
Face Value (₹) 10.00
ROCE(%) 5.47
Trade Value ( ₹ in Lacs) 8.97
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 383.15
TTM EPS (₹) 0.39
P/E Ratio 54.87
Book Value(₹) 2.72
PAT Margin (%) 1.56
Face Value (₹) 10.00
ROCE(%) 5.47

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 883.94 3756.36
Expenses N/A N/A
PBT 2.28 176.12
Operating profit 0.0 0.0
Net profit 1.16 117.44

Shareholding Pattern

Promoters (% Holding)

30.30%

Mutual funds (% Holding)

1.18%

Non-Institution (% Holding)

68.34%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.17%

About Zim Laboratories Ltd.

Founded 1984
Managing Director Anwar Siraj Daud
NSE Symbol ZIMLAB

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,52,298.64 1,885.10 1,583.70 - 1,583.70
Divi's Laboratories Ltd. 2,97,324.81 11,200.00 5,647.50 - 5,647.50
Torrent Pharmaceuticals Ltd. 1,78,727.25 4,698.80 3,672.30 - 3,672.30
Apollo Hospitals Enterprise Ltd. 1,32,138.82 9,190.05 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,29,508.26 737.00 0.00 - 0.00
Laurus Labs Ltd. 1,24,001.65 2,295.00 917.95 - 917.95
Zydus Lifesciences Ltd. 1,19,206.70 1,195.05 835.50 - 835.50
Dr. Reddy's Laboratories Ltd. 1,16,144.51 1,390.50 1,101.00 - 1,101.00
Cipla Ltd. 1,14,312.12 1,414.95 1,165.70 - 1,165.70
Mankind Pharma Ltd. 1,09,880.22 2,660.00 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Sep
18
2026
EQUITY Posted on Sep 18th 2026

Zim Laboratories informs about disclosure

With reference to the disclosure made by the Company on 11th February, 2026 regarding incorporation of a wholly owned subsidiary of the Company in Chile and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Zim Laboratories has informed that the Wholly Owned Subsidiary has been incorporated in the name of ‘ZIM Laboratories SpA’ in Santiago, Republic of Chile. The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, is also enclosed as Annexure- I.

The above information is a part of company’s filings submitted to BSE.
Read More
Nov
21
2026
EQUITY Posted on Nov 21st 2026

3B BlackBio Dx informs about outcome of schedule of analyst meeting

In continuation to earlier letter Ref. No.P-66/2026-27/55 dated 16th November, 2026 respectively, 3B BlackBio Dx has informed that the Company interacted one to one with Fortuna Asset Managers LLP, Delhi on Saturday, 21th November, 2026 at 12:00 hrs India Time. The meeting concluded at 13:00 hrs India Time. The information which is already available in public domain was discussed and no unpublished price sensitive information pertaining to the company was shared with the investor. During this investor meeting, the company reiterated the information shared by it through Investor Presentation of Q2-FY27, which was earlier intimated to the Stock Exchanges vide Ref. No.P66/2026-27/53 dated 13th November, 2026. The company has enclosed the web link of the presentation placed before investors after the declaration of the financial results for the quarter and half year ended 30-09-2026 and the above-mentioned investor. 

The above information is a part of company’s filings submitted to BSE.
Read More
Nov
21
2026
EQUITY Posted on Nov 21st 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that pursuant to SEBI Circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30 January 2026, the Company has published newspaper advertisements [All editions of Financial Express (in English) and Ahmedabad Edition of Financial Express (in Gujarati)] on 21 November 2026 containing information about the opening of Special Window, for a period of one year from 05 February 2026 to 04 February 2027, for transfer of physical shares, which were sold/purchased prior to 01 April 2019, including such transfer requests which were submitted earlier and were rejected or returned or not attended to due to deficiency in the documents/ process/or otherwise. Copies of newspaper clippings are attached as Annexure-A, which is also available on the Company’s website at www.sunpharma.com In addition to the above, the Company will publish posts on social media platforms, viz. X, LinkedIn, and Facebook regarding the aforementioned special window.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
21
2026
EQUITY Posted on Nov 21st 2026

Chennai Meenakshi Multispeciality Hospital informs about newspaper advertisement

Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in accordance with the SEBI Circular HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated 30th January 2026, Chennai Meenakshi Multispeciality Hospital has informed that it enclosed the copies of the newspaper advertisement published for the Equity Shareholders of the Company regarding the Special Window for Transfer and Dematerialisation of Physical Securities. The said advertisement was published in Financial Express & Makkal Kural Newspaper on Saturday, 19th November 2026. 

The above information is a part of company’s filings submitted to BSE.

Read More
Nov
21
2026
EQUITY Posted on Nov 21st 2026

Natco Pharma informs about press release

Natco Pharma has enclosed the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the US Food and Drug Administration (FDA) inspection at the Formulations Manufacturing facility located in Kothur, Hyderabad, India, from 12th November to 20th November, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Zim Laboratories Ltd. ?

The current share price of Zim Laboratories Ltd. is ₹147.80 as of 2026-11-20.

The market capitalisation of Zim Laboratories Ltd. is ₹793.88 as of 2026-11-20.

The 1-year return of Zim Laboratories Ltd. is 74.39% as of 2026-11-20.

The P/E ratio of Zim Laboratories Ltd. is 54.87 as of 2026-11-21.

The 52-week high and low of Zim Laboratories Ltd. are ₹159.81 and ₹59.31, respectively, as of 2026-11-20.

The dividend yield of Zim Laboratories Ltd. is 0.0% as of2026-11-20.

You can buy Zim Laboratories Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Zim Laboratories Ltd. is Anwar Siraj Daud.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore